Met Life Investment Management, LLC Ultragenyx Pharmaceutical Inc. Transaction History
Met Life Investment Management, LLC
- $17.1 Billion
- Q3 2024
A detailed history of Met Life Investment Management, LLC transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 5,681 shares of RARE stock, worth $257,633. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,681
Previous 5,608
1.3%
Holding current value
$257,633
Previous $230,000
36.96%
% of portfolio
0.0%
Previous 0.0%
Shares
67 transactions
Others Institutions Holding RARE
# of Institutions
329Shares Held
85.9MCall Options Held
520KPut Options Held
406K-
Vanguard Group Inc Valley Forge, PA9.95MShares$451 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.6MShares$254 Million0.01% of portfolio
-
Sands Capital Management, LLC Arlington, VA5.12MShares$232 Million0.91% of portfolio
-
Wellington Management Group LLP Boston, MA4.17MShares$189 Million0.04% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.07MShares$139 Million0.02% of portfolio
About Ultragenyx Pharmaceutical Inc.
- Ticker RARE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,036,896
- Market Cap $3.18B
- Description
- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...